MannKind Corporation (NASDAQ: MNKD) announced it will present new clinical and real-world data on Afrezza inhaled insulin at the Advanced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE